The process of manufacturing a biotherapeutic drug entails numerous quality control measures to ensure safety and efficacy. The articles in this in-depth focus discuss higher order structure analysis and host cell protein contamination issues.
List view / Grid view
Filter the results
The detection of crystal nucleation has taken a step forward, after French scientists developed a new method of identification.
25 January 2007 | By EPR
In a previous article the important role of protein crystallography in the optimisation of drug candidates was highlighted1. An essential part of this process is establishing robust protein crystallisation systems that can be used for both soaking and co-crystallisation experiments. This may mean producing many hundreds of X-ray quality crystals…
28 September 2006 | By Bart Hazes, Dept. of Medical Microbiology & Immunology, University of Alberta and Bernhard Rupp, q.e.d. life science discoveries, inc.
Protein crystallography has been embraced by the pharmaceutical industry to accelerate and rationalise the drug development process. In this role, success rates, throughput and turnaround times have become key competitive factors, and nearly every stage in the protein crystallography process has been targeted for automation using robotics and advanced software.…
22 August 2005 | By Professor Naomi E. Chayen, Biological Structure and Function Section, Division of Biomedical Sciences, Imperial College London
We are currently living in an exciting age, where for the fist time ever, human diseases are being understood at a molecular level. Protein crystallography plays a major role in this understanding because proteins, being the major machinery of living things, are often the targets for drugs.